Title

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
Comparison of Rosiglitazone Versus Glyburide on Vascular Structure and Function in Type 2 Diabetic Patients
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Study Participants

    36
The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.
Rosiglitazone and glyburide are two commonly used diabetic medications that have both been shown to be effective in controlling blood glucose levels. Since they work in different ways, they may have different effects on the health of the blood vessels. This study will assess which medication is better at improving the health of the arteries separate from the blood glucose lowering effects. Artery health will be assessed non-invasively by ultrasound. Certain markers of atherosclerosis found in the blood will also be measured.
Study Started
May 31
2003
Primary Completion
Dec 31
2005
Study Completion
Dec 31
2005
Results Posted
Aug 09
2012
Estimate
Last Update
Jul 15
2013
Estimate

Drug rosiglitazone

Drug glyburide

Rosiglitazone Experimental

Glyburide Active Comparator

Criteria

Inclusion Criteria:

Age 25-75 years
Type 2 diabetes mellitus for less than or equal to 10 years
Pre-screening HbA1c > 6.5 %
Screening 110 mg/dl < fasting plasma glucose < 240 mg/dl after 2 weeks of metformin 500 mg twice daily (b.i.d.)

Exclusion Criteria:

Thiazolidinedione or sulfonylurea use in previous 30 days (may undergo washout period of 30 days)
Known contraindications to use of thiazolidinedione or sulfonylurea
Female patients must be postmenopausal, surgically sterile, or using adequate contraception
Uncontrolled hyperlipidemia according to American Heart Association (AHA) guidelines
Subcutaneous insulin use
Elevated liver enzymes (2.5 times the upper limit of the reference range)
Serum creatinine >160 mmol/l
Anemia (Hb <11 g/dl for men or <10 g/dl for women)
Body mass index (BMI) <22 or >42 kg/m2
History of ketoacidosis
Angina/New York Health Academy class III/IV cardiac insufficiency
Electrocardiographic evidence of marked left ventricular hypertrophy
Uncontrolled hypertension according to AHA guidelines
Hemoglobinopathy

Summary

Rosiglitazone

Glyburide

All Events

Event Type Organ System Event Term

Flow Mediated Dilation

Measure of endothelial function

Rosiglitazone

6.8
percent change (Mean)
Standard Deviation: 3.7

Glyburide

5.5
percent change (Mean)
Standard Deviation: 3.1

Total

36
Participants

Age Continuous

60.2
years (Mean)
Standard Deviation: 8.5

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Rosiglitazone

Glyburide